openPR Logo
Press release

Oxford Gene Technology and Abcodia form Partnership

11-10-2011 05:47 AM CET | Science & Education

Press release from: Oxford Gene Technology

/ PR Agency: Alto Marketing
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a collaborative agreement with Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency™ microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Abcodia will bring their expertise in experimental design and analysis.

At present, the prognosis for someone diagnosed with pancreatic cancer is poor. The limitations of current diagnostic techniques mean that often the cancer is not detected until after it has spread. The identification of sensitive and specific biomarkers that allow early detection of pancreatic cancer could therefore significantly increase survival rates.

Julie Barnes, Chief Executive Officer, Abcodia said: "We are very excited to be able to form this strategic partnership with OGT. The combination of the breadth of the OGT technology with our unique serum biobank provides a real opportunity to significantly advance the field of early pancreatic cancer diagnosis and screening."

John Anson, Vice President Biomarker Discovery, OGT commented: "A common challenge in discovering novel cancer biomarkers is the availability of well characterised samples for the disease area of interest. We are delighted that, through our partnership with Abcodia, we are able to employ our unique and integrated genomic and proteomic array technologies to identify sensitive and specific biomarkers for pancreatic cancer."

Financial details of the partnership were not disclosed.

For more information about OGT’s cytogenetic, genomic and biomarker solutions visit www.ogt.co.uk.

Notes for editors:

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

About Abcodia
Abcodia is a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases. The company’s prospective biobank has over 5,000,000 serum samples derived from more than 200,000 initially healthy volunteers, 50,000 of whom have provided samples annually, making this an ideal resource for identifying biomarkers for disease screening. www.abcodia.com.

Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk
W: www.ogt.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oxford Gene Technology and Abcodia form Partnership here

News-ID: 199854 • Views: 1371

More Releases from Oxford Gene Technology

OGT Launches New Website Providing Authoritative Resource Aiding Molecular Medic …
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has launched its brand new website. The new content-rich site provides authoritative insight into the latest developments, tools and issues in genomics research. Intuitive navigation makes it easy for users to find relevant resources matching their requirements, including insightful whitepapers and application notes, discussion topics via the new forum section, as well as detailed
OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will

All 5 Releases


More Releases for OGT

OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will
OGT aids research into molecular genetic disease
Unique CytoSure™ Molecular Testing Arrays provide high throughput CNV detection for multiple disorders on a single chip Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a new range of CytoSure™ Molecular Testing Arrays and Panels. The new DNA microarrays utilise a unique collection of probes for detecting copy number variations (CNVs) within genes associated with a variety of disorders. Three
OGT sequencing workshop at ESHG 2011 attracts over 130 delegates
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built
Data from microarrays co-developed by OGT to be presented at ECC 2011
Talk will deliver new insights into the association of copy number variation and a range of developmental disorders Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July). Professor Joris Vermeesch, Head of the Laboratory for Cytogenetics and Genome Research at Katholieke Universiteit Leuven will present